Thromb Haemost 1977; 38(02): 0514-0523
DOI: 10.1055/s-0038-1651858
Original Article
Schattauer GmbH

Treatment of Anti-Factor VIII Antibodies

Philip M. Blatt
1   Departments of Medicine, Pathology, Pediatrics, and Dental Research Center, University of North Carolina School of Medicine, Chapel Hill, North Carolina 27514, U.S.A.
,
Gilbert C. White II
1   Departments of Medicine, Pathology, Pediatrics, and Dental Research Center, University of North Carolina School of Medicine, Chapel Hill, North Carolina 27514, U.S.A.
,
Campbell W. McMillan
1   Departments of Medicine, Pathology, Pediatrics, and Dental Research Center, University of North Carolina School of Medicine, Chapel Hill, North Carolina 27514, U.S.A.
,
Harold R. Roberts
1   Departments of Medicine, Pathology, Pediatrics, and Dental Research Center, University of North Carolina School of Medicine, Chapel Hill, North Carolina 27514, U.S.A.
› Author Affiliations
Further Information

Publication History

Received 10 May 1977

Accepted 24 May 1977

Publication Date:
04 July 2018 (online)

Preview

Summary

Bleeding episodes in patients with hemophilia A with anti-factor VIII antibodies are frequently difficult to treat. Factor VIII concentrates administered by continuous infusion or prothrombin complex concentrates (PCC) have been used for treatment. Hemophilia A patients with inhibitors who respond to factor VIII concentrates generally have low to moderate inhibitor titers (generally less than 20 Bethesda units). Those patients who receive PCC are quite difficult to evaluate but promising clinical responses have clearly been observed. This paper describes our experience with both modalities of therapy and will offer specific guidelines for such therapy.